nab-paclitaxel/carboplatin induction in squamous NSCLC: longitudinal quality of life while on chemotherapy. Thomas M, Spigel DR, Jotte RM, McCleod M, Socinski MA, Page RD, Gressot… Longitudinal quality of life while on chemotherapy
Measuring Quality Is Complicated Patt D, Page R. J Oncol Pract. 2017 Dec 6:JOP2017027789. doi: 10.1200/JOP.2017.027789. [Epub ahead of print] No abstract available. PMID: 29211577
Financial Conflicts of Interest Among Oncology Clinical Pathway Vendors Daly B, Bach PB, Page RD. JAMA Oncol. 2017 Dec 21. doi: 10.1001/jamaoncol.2017.4473. [Epub ahead of… Financial Conflicts of Interest Among Oncology Clinical Pathway Vendors
Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. BACKGROUND:The… Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS)
The VeriStrat 1 (VS) test is intended to help guide treatment decisions for patients with advanced non-small-cell lung cancer (NSCLC) without an EGFR-sensitizing mutation, classifying… Impact of a multivariate serum-based proteomic test on physician treatment recommendations for advanced non-small-cell lung cancer.
RECORD-3 compared everolimus and sunitinib as first-line therapy, and the sequence of everolimus followed by sunitinib at progression compared with the opposite (standard) sequence in… Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC.
Stomatitis is a class effect associated with the inhibition of mTOR and is associated with everolimus therapy for breast cancer. Topical steroids might reduce stomatitis… Prevention of everolimus-related stomatitis in women with hormone receptor-positive, HER2-negative metastatic breast cancer using dexamethasone mouthwash (SWISH): a single-arm, phase 2 trial.
Stomatitis is a class effect associated with the inhibition of mTOR and is associated with everolimus therapy for breast cancer. Topical steroids might reduce stomatitis… Prevention of everolimus-related stomatitis in women with hormone receptor-positive, HER2-negative metastatic breast cancer using dexamethasone mouthwash (SWISH): a single-arm, phase 2 trial.
https://www.ncbi.nlm.nih.gov/pubmed/28282276
This phase II, open-label study was designed to evaluate the response rate to the polo-like kinase 1 (Plk-1) inhibitor BI 2536 in patients with sensitive-relapsed… An open-label, phase II study of the polo-like kinase-1 (Plk-1) inhibitor, BI 2536, in patients with relapsed small cell lung cancer (SCLC).